AI Engines For more Details: Perplexity Kagi Labs You
Antibacterial Activity: Thiostrepton belongs to the class of drugs known as thiopeptide antibiotics. It exhibits potent antibacterial activity against a wide range of Gram-positive bacteria, including certain strains of staphylococci, streptococci, and other pathogens. Thiostrepton works by inhibiting bacterial protein synthesis, specifically targeting the bacterial ribosome.
Topical Applications: In human medicine, thiostrepton is primarily used in topical formulations, such as creams or ointments, for the treatment of superficial skin infections caused by susceptible bacteria. These infections may include impetigo, infected wounds, and dermatitis. Thiostrepton is often combined with other antibiotics or topical agents for broader antimicrobial coverage.
Limited Systemic Use: Thiostrepton is not commonly used systemically in humans due to its potential for toxicity and the availability of safer and more effective antibiotics for systemic infections. Systemic administration of thiostrepton may cause adverse effects such as gastrointestinal disturbances, allergic reactions, and potential nephrotoxicity.
Veterinary Use: In veterinary medicine, thiostrepton is used to treat various bacterial infections in animals, including mastitis in dairy cows, foot rot in sheep, respiratory infections in poultry, and skin infections in companion animals. Veterinary formulations of thiostrepton may be available in injectable, oral, or topical forms depending on the specific indication and species being treated.
Resistance: Like other antibiotics, bacterial resistance to thiostrepton can develop over time with widespread or inappropriate use. Therefore, prudent use of thiostrepton in both human and veterinary medicine is important to minimize the development of resistance and preserve its effectiveness for treating bacterial infections.
Safety Considerations: Thiostrepton should be used with caution in individuals with known hypersensitivity or allergic reactions to thiopeptide antibiotics. Additionally, healthcare providers should be aware of potential drug interactions and monitor patients for adverse effects, particularly if used concomitantly with other medications.
Pregnancy and Lactation: The safety of thiostrepton use during pregnancy and breastfeeding has not been well studied. As with any medication, pregnant or breastfeeding individuals should consult with their healthcare provider before using thiostrepton to weigh the potential risks and benefits.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.9 | 0.9 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 5.1 | 0.3 | 16 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 2.8 | 2.9 | -0.04 |
| Allergies | 6.3 | 4.3 | 0.47 |
| Allergy to milk products | 1.7 | 1 | 0.7 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 6.9 | 6.9 | 0 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3.5 | 0.9 | 2.89 |
| Ankylosing spondylitis | 4.1 | 1.8 | 1.28 |
| Anorexia Nervosa | 1.6 | 3.2 | -1 |
| Antiphospholipid syndrome (APS) | 1.5 | 0.3 | 4 |
| Asthma | 5.9 | 3.4 | 0.74 |
| Atherosclerosis | 2.1 | 2.4 | -0.14 |
| Atrial fibrillation | 3.8 | 2.5 | 0.52 |
| Autism | 10.4 | 10.4 | 0 |
| Autoimmune Disease | 0.6 | 1 | -0.67 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 2.4 | 2.4 | |
| Bipolar Disorder | 1.8 | 1.4 | 0.29 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 0.6 | 0.6 | |
| Cancer (General) | 0.9 | 3.4 | -2.78 |
| Carcinoma | 4.4 | 2.6 | 0.69 |
| Celiac Disease | 3 | 4.3 | -0.43 |
| Cerebral Palsy | 1.9 | 1.3 | 0.46 |
| Chronic Fatigue Syndrome | 5.4 | 6.3 | -0.17 |
| Chronic Kidney Disease | 4.6 | 3.1 | 0.48 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 2.1 | 1.7 | 0.24 |
| Chronic Urticaria (Hives) | 0.8 | 1.8 | -1.25 |
| Coagulation / Micro clot triggering bacteria | 0.7 | 1.3 | -0.86 |
| Cognitive Function | 3.1 | 1.6 | 0.94 |
| Colorectal Cancer | 7.7 | 2.2 | 2.5 |
| Constipation | 1.5 | 0.7 | 1.14 |
| Coronary artery disease | 1.8 | 2.7 | -0.5 |
| COVID-19 | 10.9 | 14.6 | -0.34 |
| Crohn's Disease | 8.9 | 6.6 | 0.35 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 1.9 | -1.9 | |
| deep vein thrombosis | 1.7 | 1.4 | 0.21 |
| Denture Wearers Oral Shifts | 2.1 | 2.1 | |
| Depression | 11.9 | 10.1 | 0.18 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.7 | 2.6 | -0.53 |
| Endometriosis | 2 | 1.7 | 0.18 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 3.3 | 2.8 | 0.18 |
| erectile dysfunction | 0.8 | 0.3 | 1.67 |
| Fibromyalgia | 3.7 | 2 | 0.85 |
| Functional constipation / chronic idiopathic constipation | 5.4 | 4.6 | 0.17 |
| gallstone disease (gsd) | 3.1 | 1.6 | 0.94 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.4 | 1.2 | 1 |
| Generalized anxiety disorder | 2.4 | 2.2 | 0.09 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2.6 | 0.7 | 2.71 |
| Graves' disease | 1.9 | 3 | -0.58 |
| Gulf War Syndrome | 0.6 | 2.6 | -3.33 |
| Halitosis | 1.8 | 0.3 | 5 |
| Hashimoto's thyroiditis | 4.4 | 2.3 | 0.91 |
| Heart Failure | 3.9 | 2.4 | 0.63 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.4 | 0.3 | 3.67 |
| High Histamine/low DAO | 1.3 | 0.6 | 1.17 |
| hypercholesterolemia (High Cholesterol) | 0.5 | 0.6 | -0.2 |
| hyperglycemia | 1.8 | 2.2 | -0.22 |
| Hyperlipidemia (High Blood Fats) | 1.4 | 0.3 | 3.67 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 5.2 | 6.5 | -0.25 |
| Hypothyroidism | 0.5 | 0.7 | -0.4 |
| Hypoxia | 2.9 | 0.3 | 8.67 |
| IgA nephropathy (IgAN) | 1.9 | 5.5 | -1.89 |
| Inflammatory Bowel Disease | 9.7 | 10.7 | -0.1 |
| Insomnia | 2.2 | 3.5 | -0.59 |
| Intelligence | 1.1 | 0.6 | 0.83 |
| Intracranial aneurysms | 1.4 | 0.3 | 3.67 |
| Irritable Bowel Syndrome | 8.8 | 6.1 | 0.44 |
| ischemic stroke | 2.6 | 1.1 | 1.36 |
| Liver Cirrhosis | 7.7 | 5.1 | 0.51 |
| Long COVID | 6.9 | 9 | -0.3 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 0.9 | 1.6 | -0.78 |
| Mast Cell Issues / mastitis | 0.9 | 0.6 | 0.5 |
| ME/CFS with IBS | 0.5 | 1.8 | -2.6 |
| ME/CFS without IBS | 2 | 2.4 | -0.2 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 2.1 | 1 | 1.1 |
| Metabolic Syndrome | 7.5 | 9.3 | -0.24 |
| Mood Disorders | 12.5 | 8 | 0.56 |
| multiple chemical sensitivity [MCS] | 1.7 | 0.1 | 16 |
| Multiple Sclerosis | 8.4 | 6.7 | 0.25 |
| Multiple system atrophy (MSA) | 2.3 | 0.7 | 2.29 |
| myasthenia gravis | 0.3 | 0.7 | -1.33 |
| neuropathic pain | 0.3 | 3.6 | -11 |
| Neuropathy (all types) | 1.2 | 1.6 | -0.33 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 5.3 | 5.6 | -0.06 |
| NonCeliac Gluten Sensitivity | 1.9 | 0.6 | 2.17 |
| Obesity | 11.4 | 10.3 | 0.11 |
| obsessive-compulsive disorder | 5.8 | 4.6 | 0.26 |
| Osteoarthritis | 2.7 | 1.7 | 0.59 |
| Osteoporosis | 1.9 | 1.9 | 0 |
| pancreatic cancer | 1.2 | 0.3 | 3 |
| Parkinson's Disease | 9.1 | 7.4 | 0.23 |
| Polycystic ovary syndrome | 7 | 3.7 | 0.89 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.3 | -0.5 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.7 | -0.42 |
| Primary sclerosing cholangitis | 3 | 2.9 | 0.03 |
| Psoriasis | 3.8 | 3.7 | 0.03 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 8.7 | 4.4 | 0.98 |
| Rosacea | 1.2 | 0.7 | 0.71 |
| Schizophrenia | 7.6 | 3.3 | 1.3 |
| scoliosis | 1.2 | -1.2 | |
| Sjögren syndrome | 2.6 | 3.2 | -0.23 |
| Sleep Apnea | 1.9 | 1.6 | 0.19 |
| Slow gastric motility / Gastroparesis | 0.9 | 0.3 | 2 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.4 | 0.6 | 1.33 |
| Stress / posttraumatic stress disorder | 3.1 | 3 | 0.03 |
| Systemic Lupus Erythematosus | 4 | 2.4 | 0.67 |
| Tic Disorder | 1.5 | 1.8 | -0.2 |
| Tourette syndrome | 1.4 | 0.3 | 3.67 |
| Type 1 Diabetes | 4.2 | 4.4 | -0.05 |
| Type 2 Diabetes | 8.4 | 8.1 | 0.04 |
| Ulcerative colitis | 5.8 | 8.5 | -0.47 |
| Unhealthy Ageing | 5.9 | 2.7 | 1.19 |
| Vitiligo | 2.5 | 1.4 | 0.79 |
